Inhibitor Therapeutics INTI
OTC INTI
$0.08 +0.00 (+0.00%)
At close: Nov 10, 2026 · 4:00 PM EST

Inhibitor Therapeutics (INTI) Other Operating Expenses (2009 - 2020)

Updated

Inhibitor Therapeutics (INTI) posted Other Operating Expenses of $14.25 million for FY2023, up 12.9% from $12.62 million in FY2022.

Analysis

Inhibitor Therapeutics (INTI) Other Operating Expenses (2009 - 2020) Analysis & Trends

Since FY2013, Inhibitor Therapeutics has reported Other Operating Expenses for 4 years.

  • Business Quant data shows INTI's Other Operating Expenses at $12.62 million in FY2022 and -$10.00 in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Inhibitor Therapeutics 13.90 Mn 6.72 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 -10.00
Jun 30, 2013 117,324.00
Dec 31, 2012 -31,625.00
Sep 30, 2012 30,000.00
Dec 31, 2011 176,021.00
Jun 30, 2011 14,498.00
Mar 31, 2011 20,000.00
Dec 31, 2009 1.87 Mn
Sep 30, 2009 -737,349.00
Jun 30, 2009 -593,390.00
Mar 31, 2009 -435,882.00
API Access

Inhibitor Therapeutics Other Operating Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-operating-expenses&ticker=INTI&period=max&api_key=YOUR_API_KEY